Home / Pharmaceuticals / Bispecific Antibodies Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), by Application (Oncology, Autoimmune Disease, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Bispecific Antibodies Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), by Application (Oncology, Autoimmune Disease, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Dec 2018 | Report Code: 59497-12-18

Industry Outlook

The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2018 to 2026. According to the research findings presented by the World Health Organization (WHO), in 2018 cancer is responsible for the death of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer. Currently 2 drugs are approved by the U.S.FDA catumaxomab and blinatumomab. 30 bispecific antibodies are in the pipeline undergoing clinical trial studies. The competition exerted by monoclonal antibodies for the treatment of the same disease condition act as a major limitation for the bispecific antibodies market growth.

Market Synopsis

Bispecific Antibodies Market

Longer serum half-life and excellent cytotoxicity profile drive the IgG like molecule market

Immunoglobulin G (IgG) like molecule is leading the type segment for bispecific antibodies market. IgG like molecule such as catumaxomab (Fresenius Biotech and Trion Pharma), is widely employed for the treatment of malignant ascites due to its inherent features such as longer serum half-life and excellent cytotoxicity profile. Non IgG like molecule will be the fastest growing market during the forecast period owing to the recent launch of blinatumomab (Amgen, Inc.) for the treatment of refractory B-cell acute lymphoblastic leukemia on account of its smaller half-life and enhanced tissue penetration characteristics.

Bispecific Antibodies Market

Severe adverse effect related to current treatment regime and burgeoning requirement for targeted drug delivery drive oncology market growth

In the current scenario oncology is reigning the application segment for bispecific antibodies market. The factors responsible for its growth are the severe adverse effects related to current treatment regimen and burgeoning requirement of targeted drug delivery for the treatment of cancer. Bispecific antibodies has the ability to cater the current requirement in cancer treatment by redirecting immune effector cells towards tumor cells, blocking signaling pathways and targeting tumor angiogenesis. Autoimmune diseases such as plaque psoriasis and rheumatoid arthritis will be treated in the near future by employing bispecific antibodies such as IL-6R × HAS (Ablynx) and IL-17A/F (Merck Group) by blocking the proinflammatory cytokines. Few bispecific antibodies are in the pipeline which will be utilized for the treatment of ailments such as wet age related macular degeneration (AMD) and idiopathic pulmonary fibrosis.

Bispecific Antibodies Market

Increasing mortality and lack of effective treatment for cancer drive the Bispecific antibodies market in North America

North America is currently leading the geographical segment for Bispecific antibodies market. The major attributes responsible for the dominance of North America are increasing mortality and lack of effective treatment for cancer. According to the Center for Disease Control and Prevention (CDC), cancer is the second largest cause of mortality in the United States, resulting in 1 in 4 deaths due to cancer. Bispecific antibodies market in Europe is driven by factors such as increased funding by government healthcare agencies in the drug discovery and cancer prevention program. Domicile of key players such as Merck Group, F.Hoffman La-Roche AG and Janssen Global Services, LLC., etc. provide impetus to the growth of Bispecific antibodies in Europe. Asia Pacific is set to register positive growth during the forecast period 2018 to 2026 owing to rising prevalence of cancer and supportive regulatory environment for the approval and distribution of bispecific antibodies.

Bispecific Antibodies Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Bispecific Antibodies Market

Report Scope by Segments

In the scope of the report the market is segmented as follows:

By Type (2016–2026; US$ Mn)

  • Immunoglobulin G (IgG) Like Molecule
  • Non Immunoglobulin G (IgG) Like Molecule

By Application (2016–2026; US$ Mn)

  • Oncology
  • Autoimmune Disease
  • Others

Geography Segment (2016–2026; US$ Mn)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of MEA

Biopharmaceuticals companies providing Bispecific antibodies are Amgen, Inc., Ablynx, Eli Lilly and Company, F.Hoffman La-Roche AG, Janssen Global Services, LLC., Merck Group, Merrimack Pharmaceuticals, Neovii Biotech, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals.

Key questions answered in this report

  • Who are the key biopharmaceutical companies manufacturing bispecific antibodies?
  • What are the drivers, opportunities and restraints pertaining to the bispecific antibodies market?
  • What is the disease etiology of different forms of cancer and what is the mechanism of action of bispecific antibodies?
  • Which type is the largest and fastest growing in the bispecific antibodies market?
  • Which application is the largest and fastest growing in the bispecific antibodies market?
  • Which regional segment is the leading and fastest growing in the bispecific antibodies market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Bispecific Antibodies Market Portraiture
2.2. Global Bispecific Antibodies Market, by Type, 2017 (US$ Mn)
2.3. Global Bispecific Antibodies Market, by Application, 2017 (US$ Mn)
2.4. Global Bispecific Antibodies Market, by Geography, 2017 (US$ Mn)

Chapter 3. Bispecific Antibodies Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Bispecific Antibodies Market, by Key Players, 2017

Chapter 4. Global Bispecific Antibodies Market, by Type
4.1. Overview
4.2. Immunoglobulin G (IgG) Like Molecule
4.3. Non Immunoglobulin G (IgG) Like Molecule

Chapter 5. Global Bispecific Antibodies Market, by Application
5.1. Overview
5.2. Oncology
5.3. Autoimmune Disease
5.4. Others

Chapter 6. Global Bispecific Antibodies Market, by Geography
6.1. Overview
6.2. North America Bispecific Antibodies Market Analysis, 2016 – 2026
6.2.1. North America Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
6.2.2. North America Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America Bispecific Antibodies Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Bispecific Antibodies Market Analysis, 2016 – 2026
6.3.1. Europe Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Bispecific Antibodies Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Bispecific Antibodies Market Analysis, 2016 – 2026
6.5.1. Latin America Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
6.5.2. Latin America Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa Bispecific Antibodies Market Analysis, 2016 – 2026
6.6.1. MEA Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
6.6.2. MEA Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Type Portfolio
7.1.4. News Coverage
7.2. Ablynx
7.3. Eli Lilly and Company
7.4. F. Hoffmann-La Roche AG
7.5. Janssen Global Services, LLC
7.6. Merck Group
7.7. Merrimack Pharmaceuticals
7.8. Neovii Biotech
7.9. OncoMed Pharmaceuticals, Inc.
7.10. Regeneron Pharmaceuticals

FIG. 1 Bispecific Antibodies Market: Research Methodology
FIG. 2 Bispecific Antibodies: Market Segmentation
FIG. 3 Global Bispecific Antibodies Market, by Type, 2017 (US$ Mn)
FIG. 4 Global Bispecific Antibodies Market, by Application, 2017 (US$ Mn)
FIG. 5 Global Bispecific Antibodies Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global Bispecific Antibodies Market, by Key Players, 2017
FIG. 8 Global IgG Like Molecule Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 9 Global Non IgG Like Molecule Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 10 Global Oncology Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 11 Global Autoimmune Disease Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 12 Global Other Applications Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 13 U.S. Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 14 Canada Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 15 U.K. Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 16 Germany Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 17 Rest of Europe Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 18 China Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 19 Japan Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 20 Rest of Asia Pacific Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 21 Brazil Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 22 Mexico Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Latin America Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 24 GCC Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of MEA Bispecific Antibodies Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Bispecific Antibodies Market Portraiture
TABLE 2 Global Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Bispecific Antibodies Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 4 Global Bispecific Antibodies Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 6 North America Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 North America Bispecific Antibodies Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa Bispecific Antibodies Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East and Africa Bispecific Antibodies Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa Bispecific Antibodies Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 21 Ablynx: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 23 F.Hoffman-La Roche AG: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 24 Janssen Global Services, LLC.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 25 Merck Group: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 26 Merrimack Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 27 Neovii Biotech: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 28 OncoMed Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 29 Regeneron Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients